ClinicalTrials.Veeva

Menu
S

Strategic Clinical Research Group | Willow Park, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Faricimab
Aflibercept
KSI-301
KHK4951
Lampalizumab
Zimura
Abicipar Pegol
Ranibizumab
Brimonidine
Avacincaptad pegol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 45 total trials

A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability an...

Not yet enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: RBS-001 Solution for intravitreal injection
Drug: Eylea® Solution for intravitreal injection

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling
Wet Age-related Macular Degeneration
Drug: Tarcocimab tedromer
Drug: Aflibercept

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Other: Sham Procedure

This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate 4 dosing cohorts of AG-73305 administered by intravitreal inje...

Active, not recruiting
Diabetic Macular Edema
Drug: AG-73305

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, am...

Active, not recruiting
Diabetic Retinopathy
Drug: Aflibercept Injection

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Active, not recruiting
Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Drug: Placebo
Drug: OPL-0401 Dose 1

Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-1...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: OCU-10-C-110 for Injection

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Ag...

Active, not recruiting
Diabetic Macular Edema
Neovascular Age-related Macular Degeneration
Drug: D-4517.2

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with a...

Active, not recruiting
Stargardt's Macular Dystrophy
Drug: Sham
Drug: avacincaptad pegol

Trial sponsors

Roche logo
Kodiak Sciences logo
Allergan logo
Astellas logo
Kyowa Kirin logo
A
A
Ashvattha Therapeutics logo
C
Genentech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems